SYBX - Earnings call transcript Q3 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. Welcome to Synlogic's Third Quarter 2020 Conference Call. [Operator Instructions]. Please be advised that this call is being recorded. I would now like to turn the call over to Daniel Rosan, Head of Corporate Finance and Investor Relations. proceed. Please

Daniel Rosan

XXXX Good This for press plan morning, outlines website third Operator. today's us release, synlogictx.com. to and several at Investors our call. and section release conference we quarter on discuss morning, today. you, that is joining thanks on which other The Thank topics results available we the financial issued our a of

Officer; Beloff, Hava, and is Brennan, on Richard President Dr. and Interim this Chief Officer; Executive Dr. Chief me Medical Financial Joining Chief Officer. Aoife Gregg Dr. us Riese, Officer. new call Chief joining Scientific are Also appointed David

Richard the call, on our provide portfolio. quarter will third progress. an During of Metabolic Gregg will and Aoife summarize our brief for will outline and results recent a update highlights financial provide quarter, the

the remarks, our prepared Following will we for questions. your call open

remind or to undue the to of now turn with including not various And filings Aoife. as any release statements result the like are like a and Securities the statements you those comments heading begin, subject statements forward-looking described uncertainties, SEC. Act to in could on may over cautions we factors, over Actual Reform differ place in under contained heading filings date the factors, the which to under results Litigation most everyone to forward-looking “Risk any XX-K our I'd As recent under made the from numerous materially forward-looking time. risks Private “Forward-Looking” Synlogic and assumptions, hereof include or made those press our reliance statements. of that forward-looking are as These statements XXXX. change call Factors” I'd today of in

Aoife Brennan

our financial and start today Hyperoxaluria us. week of you and newest and ahead We’ve schedule, our Good Enteric for history. everyone that nine colors momentum the us the our candidate of study. most our of results are third as over to head been XXXX has to SynPheny-X entering morning into rapidly quarter am To Phase back-to-school especially me we thrilled this PKU we the Synlogic. X Thanks, thank for at recent highlight including always initiation with awesome you our And now achievements forward portfolio And Year. rich share New Dan. joining and I past like the clinical the real data months. gaining period the one true of moved feels here in clinic

as Over and and establishing built technology we on biology few the changing laser patients have our we can treatments. start synthetic rely for on by premier today focused that to have one a platform years, succeed. And team, past I discussing know want we the that are team. platform today to that I portfolio life

productive X disease, more engine of the day has those towards amongst most than something is so has of research into much power before. order. and there clinic Yes, recent the do. human short course can therapeutics in breaking one. of the INDs INDs to even biotech, sign the that Each one work is more we come day bacteria there rapidly since one of change now bringing is the and Synlogic Our small Each one more realised

forward a that before Dave, research tuning We like you multiple engine. the welcome Immunomodulation through continue programs team say our why is field label. program, numerous synthetic transformative and from us prolific am has biology look clinic granting to leadership is He has partnerships. and That Dave ideation brought is successful doing to strongly synthetic to Scientific into the a Metabolic our I who Chief would is Dave experienced adopted Officer. Dave led microbiologist already drug across execute and Dr. hunter biology of medicine. of We to to bringing power who Hava an few the words. long pleased

David Hava

Thanks, Aoife.

have scientist immunology advance warm our rigor the to medicines looking me partnering development time process of diseases, Synlogic Thank third be as none. here synthetic the are cannot notch you the in to I for join forward clinical team week. advancing The with this we deepening research to welcomed the me program top biotic past the you and second say just and quality clinical thank of of to and exception Let a for welcome. science the launch this am Metabolic This work our who and few better teams. our Synlogic weeks. efforts

Aoife Brennan

Thanks, Dave.

update an quarter. now progress the portfolio to over and Let me on our past business turn

We leverages and into consume the entering no in SynPheny are metabolites the patient to medicine our clinically pleased a which our study time human rapidly progress the deliver biotic thus substances of ability sites a to toxic progressing X we're our is offer would pipeline, disease clinical with U.S. which COVID, the tract toxic the initiated variety multiple amidst The is into pipeline Transforming really synthetic metabolites. can in Even other with has the we a study internal platform GI and PKU, wide exciting in robust, Phase as states. across clinically nine far. of metabolic interest something call meaningful platform safely now disease metabolic be been

in that speak moment. study a about depth We in will

week first declaration in power and earlier toxicology from SYNBXXXX our clinic metabolic accelerated reduce were than experience CMC six has IND reproducible more follow by an timeline earlier able Relying than months. newest of our program, typical of enteric this on we products, to the inhuman period of because hyperoxaluria candidate and expected, platform. to entered the the Our

to of an on amount on X early will of XXXX. the The of done the And escalation of the synthetic learn to SYNBXXXX across next by potential dose anti-PD combination of biotic team medicines an Our shepherding the through the the portfolio year. I Xstudy to remains the continue interim arm in share clinical monotherapy has and expand. Phase an to study update monotherapy about agent The year. continued centric we end to exceptional cohorts. SYNBXXXX we with over the team also extraordinary want on immunomodulation job track the initiation expect therapy emphasize

a team those setting readouts. occur executing we XXXX, for have opportunities done in cash of window. job careful populations. the proof-of-concept Our patient stewardship, table the all end to meaningful within our Thanks multiple of has well tremendous milestones the clinic, our By cash will into

potential As who dangerously urinary of gastric managing where by high and impaired patients those the the have will today we Roux-en-Y treatments unserved in PKU bypass for SYNBXXXX patients or feel levels hyperoxaluria with assess options of no oxalate. current

of the biotic, immunostimulatory STING SYNBXXXX tumor take presenting to well in to a intended Despite chassis, cells which into leverages feasibility, the pathway. we and the STING SYNBXXXX being continues traditional directly this efficacy enrollment bacteria biotic identify of small was apoptosis, our in study to a advancing to maximum immunology synthetic using t-cell agonists. our interaction platform areas, the to designed solid to immunomodulation our immune targeting the safety between our including Phase of molecules properties clinical X synthetic antigen a and as agonist hope SYNBXXXX bacterial By exploit produce which the study and We also COVID-XX track continue well. to dose. avoid build reduces the system programmed We're disease portfolio, advantage oncology. complex a delivering the The in demonstrate tolerated in of trial STING is as tumors. pandemic, monotherapy specifically of arm

or dose-limiting We injection there toxicities continue well generally the data SYNBXXXX are the Todate, no see and to supports that is feasible which administration. with infection tolerated. SYNBXXXX of is strain seen

monotherapy initial approaches bring an from have to will the patients. therapeutic cohorts We In to update the feel to potential share year. on variance the of we dose that we the end summary, new closer gathered great

exciting pipeline to in our a solid and We key progress upcoming made our have in execute on milestones. are position

financial to me run turn to let Gregg the over the results. Now, briefly call through

Gregg Beloff

September compared This you, with of financial as XXXX, for expenses morning, million activities with in Aoife. SYNBXXXX morning, everyone. as Phase corresponding now. well were in XXXX, associated collaboration $X driven costs X the on-going ended quarter months quarter by period the XX optimization ended Administration These study. period General medicines, $XX.X million and And as you for Research released were the the million bionic XXXX. And Synlogic’s our those SYNBXXXX well I'm with of Thank review study up to the as third the XXXX. start synthetic million XXXX. three and expenses SYNBXXXX, highlights $X.X clinical for to were we September third to the for pleased Ginkgo XX, Development and results in for $XX.X good compared same

share quarter the services for same XXXX the a Synlogic's We biotic develop consolidated been with for For $X.XX quarter share, corresponding terminated. company $XXX,XXX loss period performed of in per period $XX.X treatment XXXX. to synthetic compared of per which associated the or of with revenues under medicine a or $X.XX the in as of IBD, a reported collaboration AbbVie had of third to for agreement the net million no an to XXXX, net loss third compared XXXX. has the agreement since the Revenues in $XX.X

forward XXXX Thank to current operating the you to our the the for Richard clinical will you share $XXX cash ended updated and Under advance us keeping million to calls. programs metabolic third now other cash balance take our on quarter cash, portfolio. that through look your enable important of attention, to in I'll call you plan, over turn data we into expect turning equivalents the with months. with sheet, XXXX future and and Now, Synlogic progress investments. over to readouts the our on coming we us

Richard Riese

Thank like we to and tolerable, for especially a treatment PKU. and many new study advancing Phase continue our approach therapy welcomed. which reversible This would credit with attracted has teach This through is too proof-of-concept talk potential the of clear new as are current of and the modalities. both we amount will that development. be a the the But SYNBXXXX, SYNBXXXX about PKU to we a to of us us wide developers it study our patients approaches, range SynPheny-X. progressing caregivers, novel in you a call clinical oral you, and now behind plans PKU Gregg. drug among efforts tremendous is leave X That of I'd walk emerging to options patients why is community. safe, through

promising PKU on has shown program Our activity. initial

to We plan Phe our is study the The have X of in To across and step all is all GI consumption XXXX. Phase we to the by interest Phe the tract that ability We of reducing in to answer robust, levels. at approach of Phe patient conducting well healthy patients sites reduces procedures would in open plasma sites Inbound SynPheny-X in consume solid at It PKU the the the tract, PKU plasma initiated end is most U.S. the understand study have or patients trial consumption with GI the intuitive. oral Phe [Indiscernible] how question, and [Indiscernible] demonstrated dietary impact bridging patients that Synlogic’s Phe is in the PKU. next have in volunteers. recently in have the option home to clinic. levels understood of simple multiple

Our is approach which tract, to to introduce is medicine and our GI Phe a to biology synthetic HA. on the biomarkers TCA consume build specifically measurable, product and measurable designed produce into the

measures PKU SYNBXXXX our patients, and the for which in adult performing label of understand behaves understand validate volunteers, healthy context to production of are This in lower into biomarkers, DX SYNBXXXX. SYNBXXXX volunteers and us of of nice on we as the PD consumption. of strain way to in model Phase the Biotic better to challenge the potential Phe The healthy were Synthetic in blood X demonstrate Phe platform Phe the metabolism, able data confidence SynPheny-X with we order X we to is X. Phe and benefits between One endogenous even volunteers designed. to proof-of-concept to in the the DX and the it response dose whether the In ability saw of completed is a generate this goals solid as Phase relationship of of in study move that gives Phase strain recently the study healthy lowering oral Phe

by Phe impacted cauvin study of Phe is pegvaliase. benefit plasma of We inappropriate have designed fasted are unresponsive DX reviewed. measuring dietary similar this not challenge to that SynPheny The patients the to Phe or have in therapeutic that label and in Phase no DX state to measurement two very demonstrate volunteer after Phe a healthy is options. intake. just X and is meal the variations a They for opportunities blood [Ph] endpoint Remember, I lowering, or ineligible, measurement label Phe lowering

Phe. Phe PKU are relevant responders XX% XX% profile. patients Phe These population. is we PKU Accordingly, and is BhX only effectively of behind responsive. of competitive even show of Investigators Phe patients levels a believe consistent therapeutic, non in reversible study a lowering tolerable in we current would know, if and modest such reductions us powered population oral, The to therapies. for midst levels enrollees. reductions of left product be relatively in by out To would this carry clinically you BhX lowering study As across XX% can detect be COVID-XX. that for ensure approximately tell effective we the is Especially which

interest community. The is the us by the and treatment partnership from of patient participate PKU in advancing We caregivers has in investigative critical are clinic significant patient homes, or been design The engage a devastating for to welcoming, patients directly very spirit inbound terrific a advocates, for community feedback. to advocacy driven patients this using with which a disease. response other in new willingness and with and their flexible design and of can with sponsors in options

in forward this We study looking and the executing middle of XXXX. sharing results are to

SYNBXXXX update in on let Now program, me you hyperoxaluria. newest our enteric

We these dangerously bowel other bowel levels. with patients this are urinary potential Often patients high to inflammatory such oxalate with serious as or oxalate Since the program conditions, living obesity, enthusiastic disease, chronic are about short is syndrome. patients help foods at alone. with available nephrocalcinosis, There to treatments. risk disease. almost stones and serious healthy many are control diet for these in present are means complications, hyperoxaluria This kidney chronic kidney currently is enteric of no impossible

ahead our first schedule, of We that initiated are Phase of pleased the to study dosed. been announce cohort and volunteers have Xclinical healthy has been

is to informed metabolite learnings which ability can hyperoxaluria few approach Our consume something The in from our a the accomplish. enteric toxic by PKU. tract to modalities is GI

do hyperoxaluria multiple biology, well patients. shared we We data, preclinical in patients. and demonstrated Building is oxalate are urinary designing XX% is in in XX% rationally urinary kidney meaningful possible enteric encouraging based levels our does just into validated oxalate at week. animal data reduction suggesting to as on meaningful of damage that. predictive reduction urinary medicines, a with which correlated Silico synthetic the kidney are in dietary to recently which as models of a That on simulations, hyperoxaluria and oxalate biotic oxalate in SYNBXXXX, clinic in moving

indication critical set SYNBXXXX cohort such straightforward of this this hyperoxaluria. post diseases, with initial optimal Our Roux-en-Y related provides readouts rapid hyperoxaluria The clinical for quite patients an clearly bypass in path to population plan to bowel Because development urinary volunteer can us give underlying MAD disease the for lower surgery. opportunity on as gastric will a relatively proof-of-concept hyperoxaluria sponsors after gastric by the in ability heterogeneous, patients healthy be regulatory bypass focusing, and assess study precedent enteric the significant capturing primary is oxalate. with relatively by

For oxalate of urinary is endpoint. the critical one importance

with to we regulatory work clinical closely authorities our strategy. as will develop We continue

clinically urinary XX% oxalate Our initial investigators assessment in suggests lowering will be relevant feedback greater levels. meaningful. evaluate from And our efficacy would reductions than key

Aoife now, forward of we study unfold. let But I Phase in proof-of-concept back hyperoxaluria Aoife? both and the with these PKU, As to details our hand with proof-of-concept move to you our study up. back enteric as to in studies Phase call will X come X me wrap

Aoife Brennan

team in biology for and to to Thank opportunities opportunities over abundant platform, brings high leading of I are come. to part board, made strongest. we and synthetic by the progress it is at with with The the we of work built have their And It encouraged to in data-rich once portfolio flying a season quality forward rapid our make execution multiple advancing look you, for dedicated thanking in and our these for clinical Synlogic. key the the again across end team. such COVID. biotic Together, the even endpoints at I'm employees programs to Richard. by driving challenges synthetic the year. indications period has and next want team, changing together, to Synlogic premier their with is we meaningful colors be multiple families success energizing to changes dedication disease forward the through

for open now will We the questions. call

Operator

from Shrader first or Tom of Our Instructions] [Operator from question comment line the comes BTIG.

Your line is open.

Tom Shrader

at total. you going can full Good taking digging morning. for see? see XXXX about How will us cohort bit we of in of the Clinical on it Thank what you for end will the be says I'm we're patients a question. monotherapy? XX a Just the kind Trials what tell to year? dosing And little the data. many

Aoife Brennan

is much so for This Thank Tom. Aoife. your Hi, question.

So outside been set make course cohorts we're that with enrolled in I we're I on in and the in think, disclosed the happy study But how we and study. most will of arm. great been the so multiple Obviously, the we write remarks, that But to think many said enroll progress, far year. the clinicaltrials.gov, monotherapy the this when sure making protocol how haven't I be prepared from over entire data we has postings may study. want we number we subjects it very as enrolling my have the put

Tom Shrader

agonists, a preclinical data on you And just are? thoughts? monotherapy do are active any responses set your the for outside to think where of Does melanoma the gives hints? expectation, a sense And just table you sting your doses

Aoife Brennan

Yes.

said group. set previously, we've expectations to as monotherapy the think, I around So

study. all, it was basket of a First

don't may types. have melanomas. different enroll we So enroll tumor some -- we We may

design we to able patients study. the number patients guarantee non-melanoma or of how melanoma beyond So kind our a being of parse specific is or

we has initially is and to kind of And our those that animal in. our pre-clinically weigh our I we nice consistent always in with of we I philosophy I'll evaluate data we're saw been But was evaluate on of Richard website to in some And observed patients, want the saw kind some models. changes platform, here the in those And monotherapy that's cohorts. afterwards. the available to with shrinkage to think part that who performing the are in objectives, designed. all what as dig in bacteria published get of of hoping think the we've tumor for and as what terms of biomarker publicly

gathering biomarkers models, of from for But similar to design to what benchmarks robust long can our able humans. do I kind to patients. mice Richard, trial the been you the at going plan. study terms sell for to pre-clinically to at know than successful activity to we're And day-to-day looking with and add closer the right and biomarker back look we've You're a an kind kind executing this in enough clinical of there? preclinical you'd biomarkers in we in efficacy for So But the to anything in and sell am? industry be for sell have the what you've we from we know, materials tried of and change have of as very eye of some we things lots when what that been clinic. we've that like around

Richard Riese

Sure.

safety Just in points. The couple and the Phase reinforce primary of X study endpoints a are tolerability.

interested all kind relatively would we tolerated. have us that population are in the really of in mentioned, as we're a Aoife very of are I'm studies. monotherapy. Understanding heterogeneous looking going to that that. at for in doses engagement be target this interested And So patient

that's our the for goal overall monotherapy. So

Tom Shrader

Great.

Okay. much. very Exciting stuff. Thank you

Aoife Brennan

Tom. Thanks,

Operator

Thank you.

the Our Mark comment Oppenheimer. from from of comes next Breidenbach question or line

is line Your open.

Unidentified Analyst

our from Matt it's guys, Hey Mark.

Aoife Brennan

How Matt. are you? Hey,

Unidentified Analyst

variability us, SynPheny levels those in Phe tell if particularly of the the for design, Thanks I patient in wondering update over the was the assumptions. powering you're that assumptions, what's degree time? assuming natural Good could you on

Aoife Brennan

that of to some answer. is want But I pass take that's the Matt to Matt, powering over okay. Richard assumptions? you might one Richard, do to to

Richard Riese

up And sure. is a Phe mean, and there's equal ask day. just to day time them over least there's by in we Yes, And I variability diet, from measuring in levels the variability amount at about and changes Phe. and of our for driven a also patient to know our and in into to Phe down quantitate ability in variability variability your is of itself. patient asset, XX%

So those -- we we those a decrease XX% up evaluated all detect appropriate we came the population. least in have and taken with in could Phe size this that have at so into patient all

Aoife Brennan

Matt, there not lot Yes. first as do ones a to and study PKU. Quite as we're a the well,

and our being So into able of evaluate we look prior of to some and have was the powering of back those trials, to benefit assumptions. to at their kind incorporate variability that

some PKU. So days that with patients studies we from benefit prior of of do have the in

Unidentified Analyst

That sounds a cushion. like Yes. Right. reasonable

to XXXX data biopsies, what that expecting paired us if So maybe [ph] induction? are biomarkers from things maybe taking I other Or PD of we at the Can study. just this tail like turning you remind looking set? some you're should the be guess,

Aoife Brennan

do want on take that Matt to Richard, one. you

Richard Riese

Yes.

are So That's mentioned, SYNBXXXX interferon that gene stay at we data per you of bacteria days. beta, looking kinetics also for be and dependent can interferon biopsies, to tumor paired as the at tails mRNA we're the in preclinical biopsies. in suggests present itself, at looking four tumor looking We're as six alive expression. biopsies. our And the as well

if as the So we we And we're pot. be if in systemically, seeing detect cytokine looking levels, that serum think -- SYNBXXXX very then well, at interesting. would

that set engagement, assess good is which to PD complete our goal and we of So a -- here. think biomarkers really pretty big have tumor we

Unidentified Analyst

Cool. update. Thanks for the

Operator

you. Thank

from question from next the or comment Our comes Ted Sandler. of Piper Tenthoff line

Your line is open.

Ted Tenthoff

like I bowel for with going seems a approach this thinking? I'm pretty lot I update. also But a have get you. sense technology. what the the Again, a disease for PKU. you on might what lot know Thank to Thanks natural AbbVie. be were to wanting for wanted asset you. from XXXX, know Thank And your a with with you of on you get sense inflammatory IO. plans and I a that have Great. going returned

Aoife Brennan

continue makes to on over absolutely they think who I area. a what evaluate our lot sense. Chief Officer. is new make our platform, do be remarks metabolic care to call on he think, Scientific it for couple then maybe IBD Dave therapeutic of has plans Aoife Ted. And expands certainly the because kind pass able as of to here. in of Hi, application probably to a it right, very you're would I'll general I the And as Its Hava, and

is So the got collaboration. say didn't but from we some the what to assets returned, that I regenerate we need data

So strategy the we're of of that to started around some our XXX%, in you metabolic collaborations data on leverage in kind partnerships evaluating internally forward it's regenerating to dig of to which in completely anything want I kind context now immunomodulation platform of the take assets in process terms of agree those package the to them. we breadth of and consistent But generating with and company's think additional diseases Dave, of add and the focus the to as in? continue you to there in future. of data

Dave Hava

certainly an it's remain certainly And as mean, potential we And the to. metabolic some I portfolio. of mean, of platform using make as things. think we done impact of well think that reiterate in our there. the from kind the to we learnings space I a some unlock and Yes. those committed work can the biology just see space platform I I we our that there's the previous we've both

stage programs discovery on working we're some the are about excited potential and there. So

Ted Tenthoff

applied be quick products? And where that. to it Thank Is could to up seek then, advanced Alliance potentially follow Ginkgo maybe you. one something the

Aoife Brennan

Yes.

a with for Ginkgo we us with a with prototype, strain would that up optimize. to we design the to concept we'd works we'll will come is, Gingko, and how work So, build then a like and collaboration

so a synthetic the do that do biology And competitive studies from it's complex. the synthetic perspective. one to think a IBD biology They are very for I of allow broad have large a often of us things to really and you're that array think space, tools exactly I access is new And challenges right.

colitis, are through bring looking use Gingko, late partner our as kind pharma and while right in which of way chunks So end certainly of and Crohn's I the collaborate programs development development. stage for kind we'd with the ulcerative these market, of the be mid to big think the platform, of the early IBD very we and to big all

kind I all with early the generally, involved being there's So pharma big then I think the to take of But think ends IBD with muscle way on. spectrum of very through it kind requires two that Ginkgo commercial. of

would the strategy be think I as today. of that So

Now, there sub maybe we as path exactly. secure to But a forward? future, so pursuing carve Yes, the can that identify population could , Sure. niche? in Is we Right. right development yeah, we that. a see ourselves --

Ted Tenthoff

Yeah.

Great. Okay. good the keep up much you and for the answer, so Thank Thanks. work.

Aoife Brennan

Ted. Thanks,

Operator

you. Thank

comes question of from next Our comment or line from the Gbolahan Amusa Chardan.

Your line is open.

Unidentified Analyst

is this Sam in for Gbolahan. Hi,

First, progress. congrats on

from couple questions Just me.

B on you can the XXXX, dosing just Part for entiric of and update study, the For Phase provide us hyperoxaluria? enrollment an the status X that is patients the with

Aoife Brennan

overview Part an to Sam? of Richard, you providing for B of kind do question. Richard plans mind ask answer I'll Maybe that Yes. to

Richard Riese

Sure.

looking proof-of-concept. have part we mentioned going to study. overall dose these with right page XX MAD hyperoxaluria surgery. enteric to of patients levels want to And move on as of is So the two, part in an patients X. we'll plan is design in just with to one, enable at going patients crossover with hyperoxaluria. these the enteric And hyperoxaluria Roux-en-Y. just issue plan are a Part we now rapid our foray enroll where concept are not signal We And enroll we the is [ph] a be following to in We XX approximately gastric which to oxalates with a entiric use as secondary was as And cleaner urinary patients idea that wanted get initial population hyperoxaluria. here into to diverse of a patient after bypass milligrams our And to the proof our Roux-en-Y above hyperoxaluria a patient day. to

certainly we'll we cohort, get which as soon volunteer is right MAD ongoing now. the healthy that So from as data start

Unidentified Analyst

Got it.

going enrollments I wait say, to about you're for first Part A the or so -- is Part the should B? the So data thinking from data the contingent before dosing

Richard Riese

healthy maximum to Well, part we before to to volunteers the now moving then data tolerability, we're And But a determine area. hyperoxaluria B. this on dose in with second dose, study. move we in Part to the dose, we of get need tolerated with to move when get patients need be ahead going on enteric we safety we'll

Aoife Brennan

just that next running. volunteers year. to to the on And the enrolling to what And data work have there. out provided, proprietary able which on add as mid up getting to track sites disease year is to and meet patients guidance Richard the right in now We're said we're the healthy we're the we've start

Unidentified Analyst

question. more Got it. one And Great. then

XXXX, you XXXX. have in few and So oncology quite immuno the a XXXX XXXX, readouts with in

positive readouts you the across best another you one how pivotal Assuming over forward? see to do studies? And path moving expect prioritize the do board, asset for

Aoife Brennan

A Yes. Sam. question, great

we commercialization of a perspective, could our X, X a all very basis of in full through from programs taking here, that are on know, Phase for because So, this which they're rare certain the to be you out approval company with approval. or the we've for our our our pipeline. doable is really internally size. paths because call internal is think endpoints tend readouts often biomarker basis regulatory They reiterate commercialization. yet today development I defined niche biomarkers. kind I consistent a have diseases, by much of terms is efficient very done -- or critical diseases that metabolic that prescribers to very those informed strategy, subgroup of then, of the early that there strategy, have everything way We or development, like can They and on focus discussed to we very think see And either those

we bigger For opportunities, diseases envision potentially phase more that ourselves. trials, late complexity, requiring but than commercial building larger maybe have would infrastructure bigger

the that has partner a or like will melanoma be certainly, oncology. those in opportunities, case to disease area, intent Our been and always

consistent think to we've at similarly, safety time that we been the So right would the profile, we for ideally I that's that, IBD. something once efficacy de love XXXX, partner risked and have

make with with strategy, that think to focus important for metabolic our these sense. I to really execute pipeline, then, and to in the patients. build will for being the diseases. providing collaborations, broaden to So, continue it bring to we with potential the continue company pipeline, the immunomodulation on value therapeutics seed line internal opportunity Visa, our Does and programs, for But an

Unidentified Analyst

again you Thank it. Thank does. progress. on It Got And so the much. you. congrats

Aoife Brennan

you. Thank

Operator

Thank you.

from Our SVB comes Schwartz Joseph of or comment next question line from the Leerink.

line open. is Your

Unidentified Analyst

you Joe. you NexGen, talk for if X.X implement? was planning next our for Assuming than simple You there you study? to provide additional tools or know, are strain? color you on about strain? on I dialing some My the more easy is taking a Julie extensive What Could difficult your it I'm swap question. are your just Hi. bridging that? strain wondering optimization be Thanks the in could something would out SYNBXXXX. PKU anticipating questions clinic? Or transition to you how to

Aoife Brennan

the So moving strategy maybe answer forward. of then I'll part how and hand kind we Richard question, over about your to regulatory these talk to to see programs

We've can next that made. the the a us with Ginkgo some have progress. optimization, terms that very generation make year, make of in showing progress the a number data gotten of we different pleased evaluate we've I to aware, And to of work that optimal technologies been sure and with some progress and potency from So, shared you're data think enEvolv, We've strain. the working just Julie, as we we've continue continues, our that been earlier with we this R&D good really made. very help

regulators that for able be data I reference us from think that XXXX programs. allowed the that earlier is preclinical to one have the learned to and toxicology actually thing the cross we we've had experience

would a similar moved to so using clinical chassis quickly two, have in IND, raised because reason some reusable any we we're follow toxicology. And So we GRP the a perform of would we did the metabolize candidate that those organism that not IND same to from bring and producing able benign certainly, our where metabolic programs for be the to parts. we and path that anticipate is

we Gen of that us really that but experience with also really with some as Next to future So very, quickly very -- programs, think programs that go enables well. our

kind play of he of the development Gen of hand Gen first those And sees out the to in how and opportunity stop there so part maybe PKU I'll over and as how and second might and plan. terms clinical Richard

Richard Riese

Sure. Thanks Aoife.

some of and big gain one really healthy with Some in second we would to the we've of generation had clinical thoughts advantages. of volunteers their is product the want experience the

a which can versus We and biomakers measure have in XXXX, the program our with good of a as second the data general activity we have. gen we get PKU of already idea

And and be it whether comparison get our will to idea a want PKU So, tolerated develop well that's the way dose timing this is and we then, and clinical I to potencies some maximum will regulatory as evidence of determine think a high based of in in strategy. think to which product the patients purposes strains. as as of likely two pivotal humans versus for of -- volunteer second-gen prior I vital healthy dose, All the work biomarker is we But activity level study. would with and be approach will study would in the relative we each CLA kicking flying off look some it. at to would I which on XXXX think second-gen

Unidentified Analyst

from Okay, great. That's it us.

Operator

I'd additional queue. time, the for I'm you. At remarks. over the closing no Thank this any management showing to in call like turn questions back

Aoife Brennan

like just for progress we're looking thank I updated regarding today. joining us forward. to going our Great. everyone And keeping you to forward

Operator

Ladies the in today's program. participating and gentlemen, you concludes This conference. thank for

have Everyone, day. You may now a wonderful disconnect.

Synlogic (SYBX) 7 Nov 202020 Q3 Earnings call transcript